Prurigo

Galderma to Highlight Latest Science and Innovation Across Its Product Portfolio at the 2022 AAD Annual Meeting

Retrieved on: 
Friday, March 25, 2022
Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Bajaj Consumer Care, PN, Population, AD, AAD, Skin, Geography, Atopic dermatitis, Dermatology, British Journal of Dermatology, Prevalence, Safety, Epidemiology, Prurigo, Systematic review, Prurigo nodularis, Patient, Partnership, Vaccine, Pharmaceutical industry, Aesthetics

Atopic dermatitis (AD) is a chronic, debilitating inflammatory skin disease, characterized by diffuse skin lesions and constant, severe disruptive itch.

Key Points: 
  • Atopic dermatitis (AD) is a chronic, debilitating inflammatory skin disease, characterized by diffuse skin lesions and constant, severe disruptive itch.
  • [4]
    Prurigo nodularis (PN) is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated intense unrelenting itch.
  • [6]
    The global prevalence of PN is not well known as there are few studies describing the epidemiology of the condition.
  • In the U.S., the latest estimate is that PN affects 52.9 people in every 100,000.

Galderma to highlight latest science and innovation across its product portfolio at the 2022 AAD Annual Meeting

Retrieved on: 
Friday, March 25, 2022
Bajaj Consumer Care, PN, Population, AD, Skin, Geography, Atopic dermatitis, Dermatology, Prevalence, Quality of life, Safety, Prurigo, Epidemiology, Prurigo nodularis, Patient, Partnership, Pharmaceutical industry, Aesthetics

Atopic dermatitis (AD) is a chronic, debilitating inflammatory skin disease, characterized by diffuse skin lesions and constant, severe disruptive itch.

Key Points: 
  • Atopic dermatitis (AD) is a chronic, debilitating inflammatory skin disease, characterized by diffuse skin lesions and constant, severe disruptive itch.
  • [1],[2]Reported prevalence of AD varies greatly, ranging from 1% to 25% of the population depending on the geography and age range.
  • [3]AD can have a profound impact on patients' quality of life, leading to sleep difficulties, psychological complications and causing secondary skin infections (bacterial and viral).
  • [6]
    The global prevalence of PN is not well known as there are few studies describing the epidemiology of the condition.

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

Retrieved on: 
Wednesday, December 8, 2021
Bleeding, Forward-looking statement, Company, Research, Hypersensitivity, GLOBE, Patient, Knowledge, Therapy, Pharmacokinetics, Disease, Pain, Metabolic pathway, Neuroinflammation, Immune system, Safety, Annual report, Private Securities Litigation Reform Act, B cell, Quality of life, Skin, Itch, Cell, Itchy, Cancer, Hives, Irritation, Inflammation, Form 10-K, Consultant, MD, Prurigo nodularis, Scratching, Senior, COVID-19, Prurigo, Clothing, Program, Diagnosis, Intellectual property, KIT, PN, Survival, Goal, NASDAQ, Judgement, Perspiration, Risk, Allergy, Vaccine, Pharmaceutical industry

HAMPTON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of prurigo nodularis (PN).

Key Points: 
  • HAMPTON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of prurigo nodularis (PN).
  • The randomized, double-blind, placebo-controlled, Phase 1 study is evaluating CDX-0159 in patients with prurigo nodularis.
  • The primary endpoints of the study are safety and tolerability; secondary endpoints include clinical effect, pharmacokinetics and pharmacodynamics.
  • Prurigo nodularis (PN) is a skin disease that causes hard, itchy lumps (nodules) to form on the skin.

Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease

Retrieved on: 
Monday, October 25, 2021
People, Weight gain, Depression, DSQ, Quality of life, Esophageal rupture, Disease, International development, Gastrointestinal tract, Esophagus, Inflammation, Anxiety, Interleukin, Patient, Frustration, United European Gastroenterology, FDA, Food, Asthma, Polyp (medicine), Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Time, Atopic dermatitis, Allergy, Dupilumab, EOE, Skin, Regeneron Pharmaceuticals, Eosinophilic esophagitis, Eosinophil, Breakthrough therapy, Prurigo, Water, Pharmaceutical industry, Copper

EoE is a chronic and progressive type 2 inflammatory disease that damages the esophagus and impairs the ability to swallow.

Key Points: 
  • EoE is a chronic and progressive type 2 inflammatory disease that damages the esophagus and impairs the ability to swallow.
  • The current standard of care for people with eosinophilic esophagitis may only provide limited relief of their symptoms.
  • We look forward to continuing to study Dupixents potential role in addressing the underlying type 2 inflammation that can lead to eosinophilic esophagitis.
  • The Phase 3, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of Dupixent in adolescents and adults with eosinophilic esophagitis.

Galderma to Unveil Ground-breaking Data From Across Its Leading Dermatology Portfolio and Showcase Major Update for Sensitive Skincare Brand CETAPHIL® at the 2021 EADV Congress

Retrieved on: 
Tuesday, September 28, 2021
Biotechnology, Pharmaceutical, General Health, Health, Fitness & Nutrition, Cosmetics, Retail, Other Health, Consensus, Cream, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Skin, Prurigo, Population, Doxycycline, Breakthrough therapy, Consultant, Â, Prurigo nodularis, Union, Safety, Consensus decision-making, Rosacea, Industry, Neuron, Acne, Food, Disease, Bajaj Consumer Care, Onychomycosis, Q&A, Itch, CHC, Nicotinamide, Partnership, Prevalence, Risk, European Academy of Management, Inflammation, FDA, Systematic review, IL-31, Method, Face, Congress, Moisturizer, Diagnosis, Patient, Comedo, Atopic dermatitis, European Union, Research, PN, Pharmaceutical industry, Sulfur, Vaccine, Cosmetics, Medical device, Agriculture, Fused quartz

The congress will see the unveiling of exciting new data from Galderma relating to rosacea, acne, actinic keratosis, atopic dermatitis and prurigo nodularis.

Key Points: 
  • The congress will see the unveiling of exciting new data from Galderma relating to rosacea, acne, actinic keratosis, atopic dermatitis and prurigo nodularis.
  • Galderma will also showcase its latest acne treatment, AKLIEF (trifarotene) Cream, 0.005%, specifically designed for both facial and truncal acne.
  • Visitors will be able to explore highlights from the CETAPHIL portfolio of 61 products and the largest update in the brands 70-year history.
  • Galderma is a proud partner of the EADV Congress and we are thrilled to be showcasing our latest innovations and data across our dermatology portfolio.

Prurigo Nodularis Epidemiology Forecast Report 2017-2030: Focus on United States, Germany, Spain, Italy, France, and United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 16, 2021
Health, Infectious diseases, Prurigo, Prevalence, Health, Medical specialties, Clinical medicine

This report delivers an in-depth understanding of the disease, historical and forecasted Prurigo nodularis (PN) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Key Points: 
  • This report delivers an in-depth understanding of the disease, historical and forecasted Prurigo nodularis (PN) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by diagnosed prevalence of prurigo nodularis, gender-specific diagnosed prevalence of prurigo nodularis, age-specific diagnosed prevalence of prurigo nodularis, type-specific prevalent population of prurigo nodularis, and severity-specific diagnosed prevalent population of prurigo nodularis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.
  • What is the historical Prurigo nodularis (PN) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Prurigo nodularis (PN) during the forecast period (2020-2030)?

Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis

Retrieved on: 
Tuesday, December 15, 2020
Prurigo nodularis, Prurigo, Placebo-controlled study, Medical research, Monoclonal antibodies, Medicine, Health, Pyrimidines

We are pleased to announce the commencement of dosing in the Phase 2b trial of vixarelimab in patients with prurigo nodularis.

Key Points: 
  • We are pleased to announce the commencement of dosing in the Phase 2b trial of vixarelimab in patients with prurigo nodularis.
  • The Phase 2b trial is a randomized, double-blind, placebo-controlled study designed to investigate the efficacy, safety, and pharmacokinetics ofvixarelimabin patients with prurigo nodularis.
  • Kiniksas Breakthrough Therapy application was based on data from the Phase 2a clinical trial of vixarelimab in prurigo nodularis.
  • The Phase 2b trial is a randomized, double-blind, placebo-controlled study designed to investigate the efficacy, safety, and pharmacokinetics ofvixarelimabin reducing pruritus in subjects with prurigo nodularis.

Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis

Retrieved on: 
Monday, November 16, 2020
Prurigo nodularis, Prurigo, Health, Breakthrough therapy, Clinical medicine

Kiniksas Breakthrough Therapy application was based on data from the Phase 2a clinical trial of vixarelimab in prurigo nodularis.

Key Points: 
  • Kiniksas Breakthrough Therapy application was based on data from the Phase 2a clinical trial of vixarelimab in prurigo nodularis.
  • The FDA granting Breakthrough Therapy designation to vixarelimab for the treatment of pruritus associated with prurigo nodularis is an important step forward for patients, said Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa.
  • The Phase 2a study of vixarelimab in prurigo nodularis demonstrated encouraging results in both pruritus and nodule response.
  • The FDA granted Breakthrough Therapy designation to vixarelimab for the treatment of pruritus associated with prurigo nodularis in 2020.

Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity

Retrieved on: 
Thursday, November 5, 2020
Clinical research, Design of experiments, Health sciences, Health, Medical research, Prurigo, Drug discovery, Pharmaceutical industry, Clinical trial, Placebo-controlled study

Kiniksa continues to execute across its pipeline, said Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa.

Key Points: 
  • Kiniksa continues to execute across its pipeline, said Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa.
  • Additionally, data are expected from a randomized, double-blind, placebo-controlled investigator-initiated study in theU.S.in the fourth quarter of 2020.
  • Kiniksa expects to initiate a dose-ranging Phase 2b clinical trial of vixarelimab in prurigo nodularis in the fourth quarter of 2020.
  • Total operating expenses for the third quarter of 2020 totaled $43.2 million, compared to $30.4 million for the third quarter of 2019.

Kiniksa Announces Phase 2 Clinical Data from Vixarelimab in Prurigo Nodularis to be Presented at European Academy of Dermatology and Venereology Virtual Congress

Retrieved on: 
Thursday, October 29, 2020
Prurigo nodularis, Prurigo

Prurigo nodularis is a debilitating chronic inflammatory skin condition characterized by severely pruritic skin nodules.

Key Points: 
  • Prurigo nodularis is a debilitating chronic inflammatory skin condition characterized by severely pruritic skin nodules.
  • In the Phase 2a study, vixarelimab demonstrated significant reductions in pruritus in this disease for which there are currently no FDA-approved therapies.
  • In the Phase 2a trial, vixarelimab was well-tolerated by all subjects, and no dose-limiting adverse experiences were observed.
  • Kiniksa expects to initiate a dose-ranging Phase 2b clinical trial of vixarelimab in prurigo nodularis in the fourth quarter of 2020.